Unique Anti-Glioblastoma Activities of Hypericin Are at the Crossroad of Biochemical and Epigenetic Events and Culminate in Tumor Cell Differentiation

por Dror, Naama, Mandel, Mathilda, Lavie, Gad
Publicado 2013

Advances in Microbial Biofilm Prevention on Indwelling Medical Devices with Emphasis on Usage of Acoustic Energy

por Dror, Naama, Mandel, Mathilda, Hazan, Zadik, Lavie, Gad
Publicado 2009

Cytokine prediction of mortality in COVID19 patients

por Mandel, Mathilda, Harari, Gil, Gurevich, Michael, Achiron, Anat
Publicado 2020

Degradation of HIF-1alpha under Hypoxia Combined with Induction of Hsp90 Polyubiquitination in Cancer Cells by Hypericin: a Unique Cancer Therapy

por Barliya, Tilda, Mandel, Mathilda, Livnat, Tami, Weinberger, Dov, Lavie, Gad
Publicado 2011

Unique Gene Expression Patterns in Human T-cell Lines Generated from Multiple Sclerosis Patients by Stimulation with a Synthetic MOG Peptide

por Mandel, Mathilda, Gurevich, Michael, Lavie, Gad, Cohen, Irun R., Achiron, Anat
Publicado 2005

Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?

por Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Gurevich, Michael
Publicado 2021

SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects

por Achiron, Anat, Gurevich, Michael, Falb, Rina, Dreyer-Alster, Sapir, Sonis, Polina, Mandel, Mathilda
Publicado 2021

COVID‐19 Alpha Variant (B.1.1.7): Humoral, memory B and T cells in COVID‐19 pediatric convalescents

por Gurevich, Michael, Zilkha‐Falb, Rina, Sonis, Polina, Magalashvili, David, Dolev, Mark, Mandel, Mathilda, Menascu, Shay, Achiron, Anat
Publicado 2022

SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients

por Gurevich, Michael, Zilkha-Falb, Rina, Sonis, Polina, Magalashvili, David, Menascu, Shay, Flechter, Shlomo, Dolev, Mark, Mandel, Mathilda, Achiron, Anat
Publicado 2022

Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: A prospective analysis

por Menascu, Shay, Siegel-Kirshenbaum, Michal, Dreyer-Alster, Sapir, Warszawer, Yehuda, Magalashvili, David, Dolev, Mark, Mandel, Mathilda, Harari, Gil, Achiron, Anat
Publicado 2023

The intercorrelations between blood levels of ferritin, sCD163, and IL-18 in COVID-19 patients and their association to prognosis

por Volfovitch, Yuval, Tsur, Avishai M., Gurevitch, Michael, Novick, Daniela, Rabinowitz, Roy, Mandel, Mathilda, Achiron, Anat, Rubinstein, Menachem, Shoenfeld, Yehuda, Amital, Howard
Publicado 2022

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

por Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Magalashvili, David, Sonis, Polina, Dolev, Mark, Menascu, Shay, Flechter, Shlomo, Falb, Rina, Gurevich, Michael
Publicado 2021

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

por Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Magalashvili, David, Sonis, Polina, Dolev, Mark, Menascu, Shay, Flechter, Shlomo, Falb, Rina, Gurevich, Michael
Publicado 2021

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod

por Achiron, Anat, Mandel, Mathilda, Gurevich, Michael, Dreyer-Alster, Sapir, Magalashvili, David, Sonis, Polina, Dolev, Mark, Menascu, Shay, Harari, Gil, Flechter, Shlomo, Falb, Rina
Publicado 2022

In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab

por Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Magalashvili, David, Menascu, Shay, Warszawer, Yehuda, Dolev, Mark, Didikin, Maria, Harari, Gil, Sonis, Polina, Falb, Rina, Gurevich, Michael
Publicado 2023

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

por Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Dolev, Mark, Menascu, Shay, Magalashvili, David, Flechter, Shlomo, Givon, Uri, Guber, Diana, Sonis, Polina, Zilkha-Falb, Rina, Gurevich, Michael
Publicado 2021

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

por Dreyer-Alster, Sapir, Menascu, Shay, Mandel, Mathilda, Shirbint, Emanuel, Magalashvili, David, Dolev, Mark, Flechter, Shlomo, Givon, Uri, Guber, Diana, Stern, Yael, Miron, Shmuel, Polliack, Michael, Falb, Rina, Sonis, Polina, Gurevich, Michael, Achiron, Anat
Publicado 2022